Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IDE161

Small molecule · Inhibitor of poly(ADP-ribose) glycohydrolase (PARG) · developed by IDEAYA Biosciences

Phase 1/2 Most advanced trial
IDYA Developer
2 Registered trials

What is IDE161?

IDE161 is an orally bioavailable small molecule that inhibits poly(ADP-ribose) glycohydrolase (PARG), the enzyme that hydrolyzes poly(ADP-ribose) chains produced by PARP1. By blocking PAR chain hydrolysis, it attenuates DNA repair and induces mitotic arrest. It is being studied in advanced or metastatic solid tumors, including breast, ovarian, prostate, endometrial, colorectal and head and neck cancers, and small cell and neuroendocrine lung carcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
poly(ADP-ribose) glycohydrolase (PARG)
Mechanism
Inhibitor of poly(ADP-ribose) glycohydrolase (PARG)
Pathways
DNA damage repair, PARP-dependent poly(ADP-ribose) turnover, mitotic arrest
Therapy area
Oncology
Developer
IDEAYA Biosciences (IDYA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07174583 Phase 1/2 Small-cell Lung Cancer Recruiting IDYA
NCT05787587 Phase 1 Advanced or Metastatic Solid Tumors Active not recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid TumorsBreast CancerColorectal CancerEndometrial CancerExtensive Stage Small Cell Lung Cancer (ES-SCLC)Head and Neck CancersNeuroendocrine CarcinomasNSCLCOvarian CancerProstate CancerSmall-cell Lung CancerSolid Tumor Show to Express DLL3

More from IDEAYA Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.

Follow IDYA, the company behind IDE161

See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IDYA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.